SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): March 14, 2018 (March 8, 2018)

CHEMBIO DIAGNOSTICS, INC.

(Exact name of registrant as specified in its charter)

Nevada	**0-30379**	**88-0425691**
(State or other jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification Number)

3661 Horseblock Road
Medford, NY 11763
(Address of principal executive offices)
631-924-1135
(Registrant's Telephone Number)

N/A
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

ITEM 7.01. REGULATION FD DISCLOSURE.

On March 8, 2018, the Company issued a press release entitled "Chembio Diagnostics Reports Fourth Quarter and Full Year 2017 Financial Results". A copy of the press release is furnished herewith as Exhibit 99.1

On March 14, 2018, the Company posted a PowerPoint Presentation to their website entitled "Investor Presentation March, 2018." A copy of the presentation is furnished herewith as Exhibit 99.2.

The information in this Item 7.01 of this Form 8-K is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liabilities of that section. The information in this Item 7.01 of this Form 8-K also shall not be deemed to be

incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, except to the extent that the Company specifically incorporates it by reference.

ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS

Exhibit Number	Description
99.1	Press Release entitled "Chembio Diagnostics Reports Fourth Quarter and Full Year 2017 Financial Results" dated March 8, 2018
99.2	Presentation entitled "Investor Presentation March 2018" dated March 14, 2018

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

March 14, 2018 Chembio Diagnostics, Inc.

By: /s/ John J. Sperzel III
John J. Sperzel III
Chief Executive Officer

EXHIBIT INDEX

Exhibit Number	Description
99.1	Press Release entitled "Chembio Diagnostics Reports Fourth Quarter and Full Year 2017 Financial Results" dated March 8, 2018
99.2	Presentation entitled "Investor Presentation March, 2018" dated March 14, 2018

Chembio Diagnostics Reports Fourth Quarter and Full Year 2017 Financial Results

MEDFORD, NY, March 8, 2018 -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leader in point-of-care ("POC") diagnostic tests for infectious diseases, today reported financial results for the fourth quarter and full year ended December 31, 2017.

Recent Accomplishments & Highlights

- Achieved total revenue of $24.0 million of which net product sales were $19.3 million for the full year 2017, increases of 34% and 41% respectively, over prior year
- Received $8.5 million 2018 purchase commitment from Bio-Manguinhos in Brazil for DPP® HIV Assays and DPP® Leishmania Assays
- Won three-year, $15.8 million total contract value tender from the Ethiopian Pharmaceuticals Fund and Supply Agency to deliver HIV STAT-PAK® Assays between 2018-2020
- Received conditional award of $1.5 million to $4.9 million in 2018-2019 from UNICEF for DPP® Zika Systems
- Filed Premarket Approval Application for the DPP® HIV-Syphilis Assay and DPP® Micro Reader to the Food and Drug Administration, following completion of U.S. clinical trials
- Entered collaboration with AstraZeneca to develop a quantitative DPP® Assay to detect an undisclosed biomarker, from which Chembio will receive up to $2.9 million in R&D funding over 18 months
- Strengthened balance sheet with $11.0 million in net capital from underwritten public offering in February 2018

"We demonstrated strong financial performance and meaningful progress toward our strategic and operational objectives during the fourth quarter and full year 2017. We are particularly pleased with the strong growth in total revenue and product sales," said John Sperzel, Chembio's Chief Executive Officer. "Our DPP® platform is a cornerstone from which we can build and launch a meaningful pipeline of products, and as we enter 2018, we are well positioned to continue executing on several additional milestones."

Fourth Quarter 2017 Financial Results

Total revenues for the fourth quarter of 2017 were $6.0 million, an increase of 40.7% compared to the fourth quarter of 2016. Net product sales for the fourth quarter of 2017 were $4.9 million, an increase of 50.9% compared to the fourth quarter of 2016. License and royalty and R&D, milestone and grant revenues for the fourth quarter of 2017 were $1.1 million, an increase of 8.8% compared to the fourth quarter of 2016.

Product gross margin for the fourth quarter of 2017 was $1.4 million, an increase of 97.9% compared to the fourth quarter of 2016. Gross product margin percent for the fourth quarter of 2017 was 29.5% compared to 22.5% for the fourth quarter of 2016.

Other costs and expenses, representing R&D and SG&A expenses, for the fourth quarter of 2017 were $4.6 million, an increase of 7.2% compared to the fourth quarter of 2016. The $0.3 million increase was primarily due to an increase in sales and marketing expenses and professional fees.

Net loss for the fourth quarter of 2017 was $2.0 million, or $0.16 per diluted share, compared with a net loss of $2.6 million, or $0.21 per diluted share, for the fourth quarter of 2016.

Full Year 2017 Financial Results

Total revenues for 2017 were $24.0 million, an increase of 34.4% compared to 2016. Net product sales for 2017 were $19.3 million, an increase of 41.2% compared to 2016. License and royalty and R&D, milestone and grant revenues in 2017 totaled $4.7 million, an increase of 12.0% compared to 2016.

Gross product margin for 2017 was $6.4 million, an increase of 50.2% compared to 2016, the $2.1 million increase was primarily due to increased product sales volume. Gross product margin percent for 2017 was 33.1% compared to 31.2% for 2016.

Other costs and expenses, representing R&D and SG&A expenses in 2017 were $17.6 million, an increase of 9.7% compared to 2016. The $1.6 million increase was primarily due to an increase in sales and marketing expenses and professional fees.

Net loss for 2017 was $6.4 million, or $0.52 per diluted share, compared with net loss of $13.3 million, or $1.26 per diluted share, in 2016.

Cash and cash equivalents as of December 31, 2017 totaled $3.8 million.

Conference Call

Chembio will host a conference call today beginning at 4:30pm ET to discuss financial results and recent business highlights. Investors interested in listening to the call may do so by dialing (877) 407-0778 from the U.S. or (201) 689-8565 from outside the U.S. To listen to a live webcast, please visit the Investor Relations section of Chembio's website at www.chembio.com. Following the call, a reply will be available on the Investor Relations section of the company's website for 90 days. A telephone replay will be

available by dialing (877) 481-4010 from the U.S. or (919) 882-2331 from outside the U.S. using the conference ID: 26056 until 4:30pm ET on March 15, 2018.

About Chembio Diagnostics

Chembio Diagnostics, Inc. develops, manufactures, licenses, and markets rapid diagnostic tests in the growing $8.0 billion POC testing market. Chembio's patented DPP® technology platform offers significant advantages over traditional POC lateral-flow technologies and provides the Company with a robust pipeline of business opportunities in the areas of sexually transmitted disease, tropical and fever disease, and technology collaborations.

The Company markets its products directly and through third-party distributors under the brand names: DPP®, STAT-PAK®, SURE CHECK®, and STAT-VIEW®.

Headquartered in Medford, NY, Chembio is licensed by the U.S. Food and Drug Administration (FDA) as well as the U.S. Department of Agriculture (USDA), and is certified for the global market under the International Standards Organization (ISO) directive 13485. Each of Chembio Diagnostic Systems Inc. and Chembio Diagnostics Malaysia Sdn Bhd is a wholly-owned subsidiary of Chembio Diagnostics, Inc. For more information, please visit: www.chembio.com.

Forward-Looking Statements

Statements contained herein that are not historical facts may be forward-looking statements within the meaning of the Securities Act of 1933, as amended. Forward-looking statements include statements regarding the intent, belief or current expectations of the Company and its management. Such statements, which are estimates only, reflect management's current views, are based on certain assumptions, and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to Chembio's ability to obtain additional financing and to obtain regulatory approvals in a timely manner, as well as the demand for Chembio's products. Chembio undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in Chembio's expectations with regard to these forward-looking statements or the occurrence of unanticipated events. Factors that may impact Chembio's success are more fully disclosed in Chembio's most recent public filings with the U.S. Securities and Exchange Commission.

(Tables to follow)

Investor Relations Contact
Lynn Pieper Lewis
Gilmartin Group
(415) 937-5402
investor@chembio.com

CHEMBIO DIAGNOSTICS, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS

	(Unaudited) For the three months ended		For the years ended	
	December 31, 2017	December 31, 2016	December 31, 2017	December 31, 2016
REVENUES:				
Net product sales	$ 4,869,205	$ 3,226,919	$ 19,322,302	$ 13,680,107
License and royalty revenue	263,902	315,835	741,534	449,685
R&D, milestone and grant revenue	854,965	712,122	3,951,591	3,739,049
TOTAL REVENUES	5,988,072	4,254,876	24,015,427	17,868,841
COSTS AND EXPENSES:				
Cost of product sales	3,433,309	2,501,490	12,921,157	9,417,505
Research and development expenses	2,520,646	2,162,071	8,555,381	8,427,554
Selling, general and administrative expenses	2,118,383	2,164,891	9,021,439	7,595,559
	8,072,338	6,828,452	30,497,977	25,440,618
LOSS FROM OPERATIONS	(2,084,266)	(2,573,576)	(6,482,550)	(7,571,777)
OTHER INCOME (EXPENSE):				
Interest income	(2,471)	15,819	22,485	25,548
LOSS BEFORE INCOME TAXES	(2,086,737)	(2,557,757)	(6,460,065)	(7,546,229)
Income tax provision (benefit)	(88,305)	-	(88,305)	5,800,818
NET LOSS	$ (1,998,432)	$ (2,557,757)	$ (6,371,760)	$ (13,347,047)
Basic loss per share	$ (0.16)	$ (0.21)	$ (0.52)	$ (1.26)
Diluted loss per share	$ (0.16)	$ (0.21)	$ (0.52)	$ (1.26)
Weighted average number of shares outstanding, basic	12,505,844	12,026,847	12,300,031	10,622,331
Weighted average number of shares outstanding, diluted	12,505,844	12,026,847	12,300,031	10,622,331

CHEMBIO DIAGNOSTICS, INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS

- ASSETS -	December 31, 2017	December 31, 2016
CURRENT ASSETS:		
Cash and cash equivalents	**$ 3,790,302**	$ 10,554,464
Accounts receivable, net of allowance for doubtful accounts of $42,000 and $52,000 at December 31, 2017 and 2016, respectively	**2,085,340**	3,383,729
Inventories	**4,423,618**	**3,335,188**
Prepaid expenses and other current assets	**554,383**	840,145
TOTAL CURRENT ASSETS	**10,853,643**	**18,113,526**
FIXED ASSETS, net of accumulated depreciation	**1,909,232**	**1,709,321**
OTHER ASSETS:	**3,853,146**	**752,389**
TOTAL ASSETS	**$ 16,616,021**	$ 20,575,236
- LIABILITIES AND STOCKHOLDERS' EQUITY -		
TOTAL CURRENT LIABILITIES	**3,096,303**	**3,405,650**
TOTAL LIABILITIES	**3,536,825**	3,405,650
STOCKHOLDERS' EQUITY:		
Common stock - $.01 par value; 100,000,000 shares authorized, 12,318,570 and 12,026,847 shares issued and outstanding for 2017 and 2016, respectively	**123,185**	120,268
Additional paid-in capital	**62,821,288**	60,721,783
Accumulated deficit	**(50,044,225)**	(43,672,465)
Accumulated other comprehensive income	**178,948**	-
TOTAL STOCKHOLDERS' EQUITY	**13,079,196**	17,169,586
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	**$ 16,616,021**	$ 20,575,236

CHEMBIO DIAGNOSTICS, INC. AND SUBSIDIARIES
SUMMARY OF CONSOLIDATED CASH FLOWS

	For the years ended December 31, 2017	December 31, 2016
Net cash used in operating activities	$ (5,034,515)	$ (6,704,734)
Net cash used in investing activities	(1,876,954)	(668,706)
Net cash provided by financing activities	134,280	12,550,973
Effect of exhange rate changes on cash	13,027	-
(DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS	**$ (6,764,162)**	**$ 5,177,533**

Investor Presentation March 8, 2018

NASDAQ:CEMI

Rapid Tests for Earlier Treatment™™

Slide 2

Forward Looking Statements

Statements contained herein that are not historical facts are forward-looking statements within the meaning of the Securities Act of 1933, as amended. Those statements include statements regarding the intent, belief or current expectations of Chembio and its management. Such statements reflect management's current views, are based on certain assumptions, and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to, Chembio's ability to develop, manufacture, market and finance new products and the demand for Chembio's products. Chembio undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in Chembio's expectations with regard to these forward-looking statements or the occurrence of unanticipated events. Other factors that may impact Chembio's success are more fully disclosed in Chembio's most recent public filings with the U.S. Securities and Exchange Commission.

Slide 3

Mission

To develop and commercialize simple, fast and reliable point-of-care diagnostic tests that improve diagnosis or monitoring of disease

Slide 4

Chembio's Dual Path Platform (DPP®) Technology
Next-Generation Point-of-Care Technology Platform

- **Patented point-of-care (POC) technology platform**
- **Provides enhanced sensitivity vs. lateral flow technology**
- **Allows multiplexing (i.e., multiple test results from a single patient sample)**
- **Provides quantitative results when used with DPP® Micro Reader**
- **Adapts to multiple sample types (i.e., blood, oral fluid)**
- **Applies to a range of diseases and markets**
- **Includes unique sample collection device (i.e., SampleTainer®)**

See graphics

Slide 5

Chembio's Dual Path Platform (DPP®) Technology
Leveraging Our Technology Platform to Enter New Markets

Three areas of Strategic Focus:

- Sexually Transmitted Disease Business
- Tropical and Fever Disease Business
- Technology Collaborations

DPP® Technology Platform

Slide 6

HIV and Syphilis Continue as Global Health Concerns
Testing for co-infection important for pregnant women and MSM

United States (HIV)
- **1.1 million** living with HIV
- **39,782** diagnosed with HIV
- **~1 in 7 (15%)** unaware of HIV infection

United States (SYP)
- **88,042** 18% increase in cases reported to CDC (2015-2016

Global (HIV)
- **36.7 million** living with HIV
- **1.8 million** Diagnosed with HIV
- **~1.0 million** died of AIDS-related illnesses

Global (SYP)
- **~12 million** new infections/year

Source: Centers for Disease Control & Prevention (CDC) website; World Health Organization (WHO) website Data as of 12/31/2016

Slide 7

Traditional Lateral Flow HIV Products
STAT-PAK ® and SURE CHECK ® HIV Assays

Product Features & Benefits
- FDA (PMA) approved, CLIA-waived
- CE marked, WHO pre-qualified
- 2.5 - 5.0 µL blood sample
- 15 - 20 minute test time
- Specificity: 99.9%, Sensitivity: 99.7%

Commercialization
- High quality brands, marketed globally since 2007
- Sold to Public Health Clinics, POLs, Hospitals, Self Test (EU)
- Distribution Partners US: Fisher, McKesson/PSS, H. Schein, Medline, Caribbean: Isla Lab

See graphics

Slide 8

Strengthening our Core STD Business
DPP® HIV-SYP and DPP® HIV 1/2 Assays

- § DPP® HIV-Syphilis Combo Assay
  - – Chembio has a history of leadership
    - • First to receive USAID, ANVISA (Brazil), COFEPRIS (Mexico) approvals
  - – FIled application for FDA PMA Q1 2018 after completing U.S. clinical trials in Q4 2017
  - – Global screening opportunity:
    - • Pregnant women and MSM
- § DPP® HIV 1/2 Assay
  - – Received FDA (PMA) approval (2013),
  - – Received CLIA-waiver (2014) (blood and oral fluid)
  - – Superior performance vs. competitors (sensitivity)

See graphics

Slide 9

Strengthening our Core STD Business
DPP® Syphilis Screen & Confirm and SURE CHECK ® HIV Self Test

- **DPP® Syphilis Screen & Confirm Assay**
  - Simultaneously and separately detects treponemal and nontreponemal antibodies
  - Screen and confirm in only 15 minutes, with a single drop of fingerstick blood, on a single test
  - Sensitivity: 99.7%
- **SURE CHECK® HIV Self Test (Ex-US)**
  - Simple, fast, reliable HIV assay
  - Small sample: 2.5uL fingerstick
  - Integrated sample collection device
  - Sensitivity: 99.7%; Specificity: 99.9%

See graphics

Slide 10

Fever Diseases - A Growing Global Concern
Malaria, Dengue, Zika, Chikungunya, Ebola, and Others

- **Mosquito-Borne Illnesses**
  - Mosquito à world's deadliest animal
  - Responsible for 725,000 deaths/year
  - Global geographic coverage
- **Established Fever Markets:**
  - Malaria: 214MM annual infections
  - Dengue: 390MM annual infections
- **Emerging Fever Markets:**
  - Zika
  - Chikungunya
  - Ebola
- **Which Fever Threat Will We Face Next?**

See graphics

Slide 11

Fever Disease - Product Development
Chembio Collaborates with World Leading Organizations

DPP® Malaria Assay- Bill & Melinda Gates Foundation

DPP® Dengue Assay-RVR Diagnostics Sdn Bhd

DPP® Zika Assay and DPP® Zika/Dengue/Chikungunya Assay- BARDA, FIOCRUZ, CDC

DPP® Fever Panel Assay – Asia- FIND

DPP® Fever Panel Assay – Africa- The Paul G. Allen Family Foundation

DPP® Ebola Assay and DPP® Malaria/Ebola Assay - CDC

See graphics

Slide 12

Chembio is Well-Positioned to Address Zika Virus
Key Regulatory Approvals: U.S. FDA EUA, CE mark, ANVISA

- **Local Zika Transmission**
  - 2015 (Brazil) à 2018 (~90 countries)
- **Who Needs to Be Tested?**
  - Pregnant women
  - Residents and travelers (endemic areas)

- **Molecular (MDx) Test Limitations**
  - Laboratory test, venous sample
  - Detects acute infections only - not antibodies
  - High cost
- **Chembio Zika Test Advantage**
  - Convenience: POC test; fingerstick sample
  - Detects antibodies (IgM/IgG)
  - Quantitative results: DPP® Micro Reader
  - Time to result: 15 minutes
  - Low cost compared to MDx tests

Source: Centers for Disease Control & Prevention (CDC) website

See graphics

Slide 13

Chembio is Well-Positioned to Address Zika Virus

- **Local Zika Transmission**
  - 2015 (Brazil) à 2017 (~60 countries)
- **Who Needs to Be Tested**
  - Pregnant Women
  - Travelers to/from endemic Areas
  - Others?
- **Molecular (MDx) Test Limitations**
  - Laboratory test, venous sample
  - Detects acute infections only - not antibodies
  - No immediate results
  - High cost
- **Chembio Zika Test Advantage**
  - Convenience: POC Test; fingerstick sample
  - Detects Antibodies (lgM/lgG)
  - Time to Result: 15 minutes
  - Low cost compared to MDX tests

Source: Centers for Disease Control & Prevention (CDC) website

See graphics

Slide 14

DPP® Zika Assay Product Development Timeline
Demonstrates Speed of Development and Scientific Expertise

- **DPP® Zika IgM/lgG Development/Commercialization Timeline**
  - Received PGAFF grant; initiated project DPP® Zika Project – 2/16
  - Announced Zika collaboration with Bio-Manguinhos/Fiocruz (Brazil) – 3/16
  - Completed initial testing; including 600 pregnant women – 4/16
  - Announced regulatory filings with FDA-EUA, ANVISA – 5/16
  - Announced regulatory filings with WHO-EUA, Cofepris, CE mark – 7/16
  - Received CE mark (Europe, Caribbean)- 7/16
  - Announced HHS/BARDA funding contract– 8/16
  - Awarded CDC Surveillance Program: DPP® Zika/Dengue/Chikungunya (Peru, India, Guatemala, Haiti)- 9/16
  - Received ANVISA approval, DPP® Zika Assay –11/16
  - Successful INCQS Evaluation- 2017

See graphics

Slide 15

Ongoing Technology Collaborations
Leveraging Our Patented DPP® Technology Platform

DPP® "Undisclosed Biomarker" Assay- AstraZeneca
DPP® Cancer Assay- Undisclosed Collaborator
DPP® Bovine TB Assay- USDA
DPP® Concussion Assay- Perseus Science Group LLC

Slide 16

Chembio's Global Organization
Expanding Commercial and Manufacturing Operations

Manufacturing Operations
Facilities: 65,000 sq. ft.
Capacity: 25MM tests
Certification: ISO 13485
Regulatory Compliance: (FDA, WHO, USDA, ANVISA)

See graphics

Slide 17

Selected Financial Highlights

	Quarter Ended (in 000's)		9 Months Ended (in 000's)	
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2017	Dec. 31, 2016
Net Product Revenues	**$ 4,869**	**$ 3,227**	**$ 19,322**	**$ 13,680**
Total Revenues	**$ 5,988**	**$ 4,255**	**$ 24,015**	**$ 17,869**
Gross Margin	**$ 1,436**	**$ 725**	**$ 6,401**	**$ 4,263**
Loss from Operations	$ (2,084)	$ (2,574)	$ (6,483)	$ (7,572)
Net Loss	$ (1,998)	$ (2,558	$ (6,372)	$ (13,347)*
Accounts Receivable Net	**$ 2,085**	**$ 3,384**	**$ 2,085**	**$ 3,384**
Cash (as of end of period)	**$ 3,790**	**$ 10,554**	**$ 3,790**	**$ 10,554**

**The net loss in 2016 includes the non-cash impact of a $5.8 million valuation allowance on the Company's deferred tax asset.*

Slide 18

Investment Highlights

- **A global leader in point-of-care (POC) infectious disease**
  - Sales & marketing organization in U.S., LATAM, Europe, Africa, and APAC
  - Manufacturing operations in the U.S. (NY) and Malaysia
- **Groundbreaking patented DPP® technology platform**
  - Superior sensitivity and specificity vs. traditional lateral flow technology
  - Multiple tests from a tiny (10µL) drop of fingertip blood (multiplexing)
- **Robust pipeline of new DPP® POC assays in development**
  - DPP® HIV-Syphilis Combination Assay (U.S. version)
  - DPP® Fever Assays (Malaria, Dengue, Zika, Chikungunya, Ebola, + others)
  - DPP® Technology Collaborations (Cancer, Concussion, Undisclosed, Bovine TB)
- **Multiple high-value collaborations**
  - U.S. Government: HHS/ASPR/BARDA, CDC: DPP®Zika
  - AstraZeneca: DPP® "Undisclosed Biomarker"
  - Bill & Melinda Gates Foundation: DPP® Malaria
  - Paul G. Allen Ebola Program: DPP® Fever Panel - Africa
  - FIND: DPP® Fever Panel - Asia

Slide 19

Experienced Executive Leadership Team

Executive: John J. Sperzel III, President &CEO
Joined Chembio: 2014
Previous Experience: 2011-2013, President and CEO of ITC/Accriva; 1987-2011 Axis-Shield, Bayer Diagnostics, Instrumentation Laboratory and Boehringer Mannheim

Executive: Neil A. Goldman, CPA Chief Financial Officer; Executive Vice President
Joined Chembio: 2017
Previous Experience: 2015-2017, CFO of J.S. Held; 1989-2015 Unwired Technology LLC/Delphi Corp., EPPCO Enterprises, Ernst & Young

Executive: Javan Esfandiari, M.S. Chief Science and Technology Officer; Executive Vice President
Joined Chembio: 2000
Previous Experience: 1997-2000, Co-founder of Sinovus Biotech AB (Sweden), acquired by Chembio in 2000; 1993-1997 R&D Director of On-Site Biotech

Executive: Sharon Klugewicz, M.S., President, Americas Region
Joined Chembio: 2012
Previous Experience: 2009-2012, Sr. VP Scientific & Laboratory Services of Pall Corporation; 1991-2009 Pall Corporation

Executive: Robert Passas, Ph.D., President, EMEA & APAC Regions
Joined Chembio: 2016
Previous Experience: 2015-2016, VP, Worldwide Marketing and International Sales at Trinity Biotech; 1993-2015 The Binding Site, Abbott, Trinity Biotech, Quidel

Executive: Thomas Ippolito, VP Regulatory & Clinical Affairs
Joined Chembio: 2005
Previous Experience: 2000-2005, VP Quality & Regulatory of Biospecific Technologies Corp.; 1984-2000 United Biomedical Inc., Analytab Products Inc. and Eastern Long Island Hospital

Executive: Paul Lambotte, Ph.D, VP Product Development
Joined Chembio: 2014
Previous Experience: 2009 – 2014, President of PLC Inc.; 2009 – 2012 Chief Science Officer of Axxin Pty Ltd.; 2000-2009, VP of R&D and Business Development of Quidel, Inc.

Executive: David Gyorke, VP Manufacturing Operations
Joined Chembio: 2017
Previous Experience: 2011-2016, VP operations of Nanomix, 1983-2011, NeoVista, Farallon Medical, Inc., Cholestech Corporation, Bio-Rad